Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Adel Tawfilis, et al. v. Allergan, Inc.
Case Number:
8:15-cv-00307
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
August 27, 2018
Docs' Attys Win $5.7M From $13.5M Botox Pricing Deal
A California federal judge on Monday signed off on $5.65 million in fees and expenses requested by attorneys representing a class of doctors that reached a $13.45 million settlement with Allergan Inc. over allegations the company cut a deal to keep a Botox competitor off the market.
-
May 03, 2018
Docs' Attys Seek $5.7M From $13.5M Botox Pricing Deal
A solo practitioner and a six-man class action firm sought approval Wednesday to take a $5.65 million slice of a $13.45 million proposed settlement on behalf of a class of doctors with Allergan that resolved allegations the company cut a deal to keep a Botox competitor off the market.
-
February 12, 2018
Allergan To Pay $13.5M To End Doctors' Botox Pricing Suit
Allergan Inc. has agreed to pay a class of doctors $13.45 million to settle allegations it inflated the price of Botox by cutting a deal to keep a competing product off the market, according to a proposed settlement filed in California federal court on Friday.
-
October 20, 2017
Doctors Fight Allergan's Attempt To Defeat Botox Pricing Suit
A class of doctors urged a California federal court Thursday to reject Allergan's bid to end a suit accusing it of inflating the price of Botox by cutting a deal to keep a competing product off the market, bashing the drugmaker's characterization of the agreement as a standard business decision.
-
June 26, 2017
Docs Win Class Cert. In Botox Price-Inflation Action
A California federal judge on Monday certified a class of doctors accusing Allergan Inc. of inflating the price of Botox by inking an agreement with a Korean competitor that prevented it from bringing a rival product into the U.S.
-
May 31, 2016
Doctors Denied Early Win In Botox Action Against Allergan
A California federal judge on Tuesday denied a bid by two surgeons to have judgment entered in their favor in his proposed class action accusing Allergan Inc. of inflating the price of Botox, saying their request was made too soon.
-
December 15, 2015
Allergan Loses Latest Bid To Nix Botox Price-Fixing Suit
A California federal judge on Monday refused to reconsider a ruling that kept alive a proposed class action accusing Allergan Inc. of inflating the price of Botox, holding that a pair of factual errors don't affect any of her legal conclusions.
-
November 23, 2015
Botox Buyer Rips Allergan's Bid To Slip Price-Fixing Suit
The California oral surgeon behind a proposed class action accusing Allergan of inflating the price of Botox told a federal judge on Friday the drugmaker is misstating his claims in its efforts to undo the judge's recent decision not to dismiss the case.
-
October 27, 2015
Allergan Says Court Botched Facts In Botox Antitrust Suit
Allergan Inc. on Monday asked a California federal judge to reconsider its refusal to dismiss a suit accusing Allergan of keeping prices for Botox artificially high by buying rights for a competing Korean drug, saying the Korean company was required to partner with a U.S. provider to sell the drug in the country.
-
October 20, 2015
Allergan Can't Escape Botox Antitrust Suit
A California federal judge on Tuesday refused to toss a surgical center's proposed class action accusing Allergan of licensing a Korean-made drug arguably superior to its Botox treatment in order to unlawfully keep Botox prices high, saying the center adequately alleged the deal resulted in direct buyers paying higher prices.